Mein Warenkorb

RON

RON Molekülinformation

Englischer NameMacrophage-stimulating protein receptorAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel2Target-AliasRon tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameMacrophage-stimulating protein receptor
Target-AliasRon tyrosine kinase receptor,MSP Receptor,PTK8,PTK8 Protein Tyrosine Kinase 8,Macrophage Stimulating 1 Receptor,MST1R,NPCA3,S13 Avian Erythroblastosis Oncogene Homolog,CDw136,CD136,CD136 Antigen,C-Met-Related Tyrosine Kinase,EC:2.7.10.1,EC 2.7.10.1,Protein-Tyrosine Kinase 8,S13 Erythroblastosis Oncogene Homolog,RON,SEA,Macrophage-Stimulating Protein Receptor,S13 Erythroblastosis (Avian) Oncogene Homolog,P185-Ron,EC 2.7.10
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphaseApproved

RON Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag (1)

  • Marker

    Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
RON-H52H9
Human
HEK293
Human RON / MSPR Protein, His Tag (MALS verified)
In den Warenkorb legen
Gesamtmenge1
  • 1

RON Molekülhintergrund

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

RON Molekülalias

CD136 antigen,CD136,CDw136c-met-related tyrosine kinase,EC 2.7.10,EC 2.7.10.1,macrophage stimulating 1 receptor (c-met-related tyrosine kinase),MSP R,MSP receptor,MSPR,MST1R,p185-Ron,Protein-tyrosine kinase 8,PTK8 protein tyrosine kinase 8,PTK8,Ron,RONmac

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Ningetinib TosylateCT-053-PTSA; CT-053Phase 2 ClinicalHec Pharm Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms
Details
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And CompanyBiliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
CrizotinibPF-1066; PF-2341066; PF-02341066; PF-002341066ApprovedPfizer Inc赛可瑞, XalkoriUnited StatesCarcinoma, Non-Small-Cell LungPf Prism Cv2011-08-26Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns